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Patients with diabetes mellitus have an increased prevalence of vascular disease. Pathologic thrombosis associated with
atherosclerotic plaque rupture is a major cause of morbidity and mortality. Platelets are intimately involved in the initiation
and propagation of thrombosis. Evidence suggests that platelets from patients with type 2 diabetes have increased reactivity and
baseline activation compared to healthy controls. We review the pathophysiology of platelet hyperreactivity in DM patients and
its implications in clinical practice, with particular focus on acute coronary syndromes, percutaneous coronary intervention, and
novel antiplatelet agents.
1.Introduction
Diabetes mellitus, that aﬀects over 25 million people in the
US and an estimated 285 million worldwide, is associated
with a signiﬁcant burden of cardiovascular disease [1, 2]. Pa-
tients with type 2 diabetes mellitus (DM2) have a 2- to 4-
fold increased risk of premature cerebral, coronary, and pe-
ripheral vascular disease that together constitute the leading
cause of death in these patients [3, 4]. Unlike the diabetes-
speciﬁc microvasculopathy, neuropathy, nephropathy, and
retinopathy, the macroangiopathic process in patients with
diabetes represents an accelerated but pathophysiologically
similar process to atherosclerosis in nondiabetic subjects.
Thrombotic events of these vascular lesions, particularly in
the cerebral and coronary vasculature, can be life threaten-
ing.
Normal blood ﬂow and thromboresistance is dependent
on vasomotion, blood corpuscular elements, plasma com-
ponents, and their interaction with the endothelial surface.
Rupture of an atherosclerotic plaque exposes subendothelial
materialthatpromotesplateletactivationandthelocalinitia-
tionofthecoagulationcascadethatcanleadtothrombusfor-
mation at the site of endothelial disruption. Acute vascular
events, such as myocardial infarction and stroke, are due to
such atherothrombotic events rather than gradual progres-
sion of luminal stenosis caused by atheromatous plaque.
Patients with DM not only have a greater atheromatous
plaque burden but also a thrombotic diathesis that is in part
due to changes in the coagulation system with increased
levelsofplasmaﬁbrinogen,increasedintravascularthrombin
generation, and reduced ﬁbrinolytic potential [5, 6]. Equally
importantly, however, platelets from patients with diabetes
mellitus have dysregulated signaling pathways that lead to an
increased tendency to activate and aggregate in response to a
given stimulus (platelet hyperreactivity). Platelet activation
contributestothepathologybynotonlytriggeringthrombus
formation but also causing microcapillary embolization and
release of constrictive, oxidative, and mitogenic substances
that accelerate progression of local vascular lesions.
Platelet hyperreactivity and increased baseline activation
in patients with diabetes is multifactorial and associated with
biochemical factors such as hyperglycemia and hyperlipi-
demia, insulin resistance, and an inﬂammatory and oxidant
state. We aim to review the factors associated with increased
platelet reactivity in patients with diabetes mellitus, with a
predominantfocusonDMtype2.Wealsodiscusstheclinical2 International Journal of Endocrinology
relevance of platelet hyperreactivity in diabetic patients with
acute coronary instability and the possible choices of anti-
platelet agents to suppress platelet activity in this popula-
tion.
2.BiochemicalFactorsAffectingPlatelet
Function in Diabetes
Hyperglycemia is the diagnostic hallmark ﬁnding in diabetes
mellitus and is associated with macrovascular disease even
in the prediabetic stage. Hyperglycemia, particularly post-
prandial, plays a signiﬁcant role in the DM-associated devel-
opment of cardiovascular disease as well as the DM pro-
thrombotic state [7, 8].
In healthy subjects, without DM, the induction of acute
hyperglycemia can lead to increased platelet reactivity and
platelet activation as evidenced by increased markers such
as soluble P selectin and CD40-ligand [9–11]. Exposure of
platelets to hyperosmolar solutions also causes increased
reactivity, suggesting that hyperglycemia may have a direct
osmotic eﬀect [12]. Both chronic and acute hyperglycemia
causes in vivo activation of protein kinase C (PKC), a trans-
duction pathway mediator for many proaggregatory platelet
agonists [13]. Platelets from patients with DM, unlike those
fromhealthyindividuals, alsomanifestshort-termactivation
of the calcium-sensitive PKCβ isoenzyme by acute hyper-
glycemia even in vitro, in the absence of additional stimuli,
indicating an inherent diabetes-related dysregulation of this
pathway. A study of patients with type 2 DM undergoing
percutaneous coronary intervention (PCI) found that im-
provementsinglycemiccontrolwereassociatedwithreduced
platelet reactivity [14]. The clinical correlate of these changes
is that even mild elevations in preprocedural fasting glucose
associate with increased risk of mortality following PCI
and, conversely, optimal preprocedural glycemic control
(HbA1c < 7%) in type 2 DM patients is associated with
improved clinical outcome [15, 16].
Recurrent episodes of hyperglycemia lead to the nonen-
zymaticinteractionbetweenthecarbonylgroupofthereduc-
ing sugar and the primary amino group of a protein leading
to a cascade of reactions, the ﬁnal result of which is a hetero-
geneous group of compounds known as advanced glycation
end products (AGEs) [17]. Some of these AGE cause exter-
nalization of platelet membrane phosphatidylserine that
leads to surface clotting factor activation and so directly en-
hance the thrombogenic state [18]. Similarly, the platelets of
patients with diabetes have increased glycation levels of sur-
face membrane proteins which cause decreased membrane
ﬂuidityandincreasedplateletsensitivitytoagonists.[19,20].
The ﬁnal common pathway of platelet activation sig-
naling is platelet aggregation mediated by the glycoprotein
IIb/IIIa receptor (GPIIb/IIIa) platelet-ﬁbrin interaction. The
expression of platelet surface GP IIb/IIIa, as well as of GPIb,
which mediates binding to von Willebrand factor, correlates
with levels of hemoglobin A1C. Hyperglycemia leads to
release of larger platelets with more GPIb and GPIIb/IIIa
receptors and higher thromboxane forming capacity [21].
Other platelet surface receptors, such as P2Y12, the target
of widely used thienopyridine antiplatelet agents, are also
present in increased numbers on DM platelets likely as a
result of the altered membrane ﬂuidity dynamics [22]. Acti-
vation of the platelet P2Y12 receptor normally leads to re-
duced levels of cyclic adenosine monophosphate (cAMP)
and subsequently suppressed phosphorylation of vasodilat-
or-stimulated phosphoprotein (VASP-P) by speciﬁc protein
kinases (PKA) that enhances platelet activation and aggre-
gation (Figure 1)[ 23]. Platelets from patients with DM have
lower levels of cAMP compared with nondiabetics, with con-
sequently upregulated P2Y12 signaling. Platelets of older dia-
betics in particular have a higher baseline intracellular calci-
um level with more enhanced calcium mobilization from
intracellular stores in response to thrombin agonism com-
pared to nondiabetic patients [22, 24]. The higher baseline
calcium and lower cAMP make the platelets more reactive
suchthattheyactivateandaggregateatlowerlevelsofagonist
stimulation.
Abnormalities of lipid metabolism, particularly hyper-
triglyceridemia and low levels of high-density lipoprotein
(HDL), are almost invariably found in patients with im-
paired glucose homeostasis. Hypertriglyceridemia can lead
to triglyceride-rich very low density lipoprotein (VLDL)
that potentiates platelet activity, an eﬀect mediated partly
throughapolipoproteinEandaninteractionwiththeplatelet
LDL receptor [25]. Interestingly, administration of reconsti-
tuted HDL to DM patients can promote cholesterol eﬄux
from platelet membranes which suppresses aggregation [26].
Additionally, the interaction of lipids and glucose with the
formation of glycated low-density lipoprotein (LDL) leads to
impaired nitric oxide production and increased intraplate-
let calcium concentration, further contributing to platelet
hyperreactivity [27].
3. InsulinEffects on PlateletsinDiabetes
Type 2 DM accounts for 90%–95% of all DM cases and is
characterized by reduced tissue sensitivity to insulin. In the
prediabetic stage this insulin resistance is initially met by a
compensatory increase in insulin production by pancreatic
β-cells suﬃcient to maintain fasting euglycemia. In suscep-
tible individuals, the pancreatic β-cells, under the increased
demand, undergo apoptosis leading to a reduction in β-cell
mass. Consequently, the hyperinsulinemia characteristic of
theearlystagesofDM2progressivelygiveswaytorelativeand
eventually absolute insulin deﬁciency.
Insulin can directly regulate platelet function via a func-
tional insulin receptor (IR) found on human platelets [28].
The eﬀects of hyperinsulinemia on platelets, however, are
complex and disparate between normal individuals and pa-
tients with insulin resistance. In vitro experiments using
platelets from healthy nonobese individuals reveal that bind-
ing of insulin to its receptor causes magnesium to translocate
into the platelet and is associated with decreased thrombin-
induced platelet aggregation and reduced production of
proaggregatory thromboxane B2 [29]. Binding of insulin to
the IR leads to activation of the insulin receptor substrate
1 (IRS-1) through tyrosine phosphorylation which initiates
association with the Giα-subunit. The result is reduced Gi
activity that impairs tonic cAMP suppression, and thus leadsInternational Journal of Endocrinology 3
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Figure 1: Pathways involved in platelet hyperreactivity in DM patients and therapeutic targets. AGE: advanced glycation end products,
RAGE: AGE receptors, PKA/B/C: protein kinase A/B/C, MAPK: p38 mitogen-activated protein kinase, TK: tyrosine kinase, NO: nitric oxide,
GC: guanylate cyclase, PAR-1 TR: protease activated receptor; thrombin receptor, PI-3: phosphoinositol-3 kinase TRA: thrombin receptor
antagonist, TPα: thromboxane receptor, TPRA: thromboxane receptor antagonist, and ASA: acetylsalicylic acid (aspirin). Increased levels
of cAMP lead to platelet inhibition through cAMP-dependent protein kinase (PKA) which inhibits signaling though the mitogen-activated
protein kinases pathway, receptor activation, thromboxane A2 formation, and activation of key enzymes such as protein kinase C. The
prostaglandin, P2Y, P2X, TR, and TP are all seven transmembrane G-protein associated receptors. The TR and TP on the right present novel
drug targets; their intracellular eﬀectors are omitted for clarity. Antiplatelet drugs are shown in red.
to increased cAMP intraplatelet levels, blunting of P2Y12
signaling and reduced platelet activity (Figure 1)[ 30, 31]. It
has been suggested that the magnitude of such eﬀects may
be limited due to the dimerization of IR subunits with those
of the insulin-like growth factor 1 (IGF-1) receptor [32].
Nonetheless, the activation of insulin receptor substrate 1
(IRS-1) and IRS-2, the downstream mediator of the IR, can
also occur by binding of IGF-1 to the IGF-1 receptor that is
abundantlyexpressedinplateletsleadingtoincreasedplatelet
reactivity [33]. Further, in vivo, experiments in health-
y nonobese individuals conﬁrm that insulin inhibits platelet
interaction with collagen and attenuates the platelet aggrega-
tion eﬀect of agonists [34, 35].
These ﬁndings suggest that at least in healthy nonobese
individuals, insulin reduces platelet reactivity. Based on this,
one may well expect increased platelet reactivity in DM type
1patientswhohaveabsoluteinsulindeﬁciency.Similarly,one
may postulate that patients with prediabetes or early stages
of DM2 who have hyperinsulinemia should have suppressed
platelet activity. This is, however, far from being the case.
Obesity, a common feature in DM2 patients, can exacerbate
or induce insulin resistance yet is associated with platelet
hyperreactivity [36]. A euglycemic hyperinsulinemic clamp
in obese insulin-resistant patients fails to suppress platelet
activity even in the absence of overt DM [36]. Furthermore,
obese patients have evidence of increased platelet activation
with increased plasma CD40L, increased levels of platelet
derived microparticles (released in blood by platelet activa-
tion), and higher thromboxane production [37–40]. Insulin
sensitization by pioglitazone or weight loss reduces markers
of platelet activation in obese women [37, 39].
The mechanism underlying these discrepant eﬀects of
insulin on the platelets of healthy individuals versus patients
with insulin resistance appears to be impairment of the
insulin receptor signaling pathway that occurs not only in
tissues but also in platelets [22]. The reduced platelet insulin
sensitivity leads to lower cAMP levels, increased intraplatelet
calcium concentration, and platelet hyperreactivity [22, 41].4 International Journal of Endocrinology
Indeed, insulin therapy in patients with type 2 DM may lead
to paradoxical increases in platelet reactivity in vivo [42].
Additionally, platelets from DM patients show IRS-inde-
pendent impairment of sensitivity to prostacyclin and nitric
oxide that normally blunt platelet activation that leads to
further increases in platelet reactivity [43, 44].
Hyperinsulinemia is, therefore, not protective but poten-
tiallydetrimentaltoplateletreactivityinpatientswithinsulin
resistance. In addition to its platelet action, insulin has other
adverse prothrombotic eﬀects. Induced hyperinsulinemia,
particularly in combination with hyperglycemia, leads to a
procoagulant state by increasing levels of tissue factor pro-
coagulant activity, decreasing factor VII/VIIa and increasing
factorVIIIandprothrombinfragmentF1.2[11].Inaddition,
there is upregulated platelet expression of CD40L and in-
creased monocyte-platelet aggregates, indicative of platelet
activation that appears distinct to the pathways of activation
by other agonists [45].
4. Effects of OxidativeStress andInﬂammation
on Platelet Function
Patients with DM have evidence of increased oxidative stress
and inﬂammation compared with healthy subjects. DM
is associated with an overproduction of reactive oxygen
and nitrogen species and potent radicals, such as hydrogen
peroxide and superoxide anion, that can directly lead to
platelet activation [46–48]. DM patients have higher levels of
8-iso-prostaglandin F2α (8-iso-prostane), a product of non-
enzymatic arachidonic acid peroxidation and marker of oxi-
dative stress, particularly in association with acute hypergly-
cemic episodes [49–51]. Oxidative stress can directly aﬀect
platelet reactivity as superoxide anions enhance intraplatelet
calcium release upon platelet activation, helping to amplify
the platelet aggregation response [52].
T h er e a c t i v eo x y g e ns p e c i e se n h a n c et h ei n t e r a c t i o no f
sugars with proteins during recurrent episodes of hypergly-
cemia and increase the rate of accumulation of previously
mentioned advanced glycation end products (AGEs). These
products can interact with AGE receptors (RAGEs) on the
endothelium inducing endothelial dysfunction and an in-
ﬂammatory response (Figure 1)[ 53]. Normal endothelium
produces nitric oxide (NO) and prostacyclin which inhibit
platelet activation under physiological conditions. Endothe-
lial dysfunction leads to reduced production on NO and
prostacyclin and so contributes to platelet hyperreactivity
[54,55].NOcanbeoxidizedbysuperoxideanions,leadingto
further reductions in its half-life and antiplatelet action [52].
Inﬂammation, associated with endothelial dysfunction,
modulates the levels of proteins involved in platelet activa-
tion, such as increasing levels of the Fcγ-RIIA receptor that
mediates enhanced activation in response to collagen [56].
Both oxidative stress and inﬂammation are also associated
with accelerated turnover of platelets in patients with DM
compared with healthy individuals, as indicated by the ﬁnd-
ing of immature, reticulated circulating platelets [57]. As
platelet size correlates with activity, these large platelets are
inherently hyperreactive and less responsive to antiplatelet
therapy with aspirin and clopidogrel [58, 59].
5.ClinicalImplicationsof Platelet
Hyper-ReactivityinDiabetes
Low-dose aspirin remains the cornerstone of antiplatelet
therapy by reducing the risk of MI, stroke, or cardiovascular
death in intermediate-to-high-risk patients with established
vascular disease by 20% [60]. Nonetheless, some patients’
platelets remain reactive despite aspirin therapy when as-
sessed by in vitro laboratory tests using a variety of platelet
agonists. Multiple studies have found these patients to be at
higherriskofatherothromboticevents[61–65].Theproblem
is particularly prominent in DM patients, 10%–40% of
whomdisplayhighresidualplateletreactivityonbiochemical
testing despite aspirin therapy [66, 67]. Although often
termed“aspirin resistance”, thisis, in most cases,a misnomer
as failure of aspirin to achieve its expected pharmacological
eﬀect of inhibiting the conversion of arachidonic acid to
TXA2 by the platelet cyclooxygenase-1 (COX-1) enzyme is
actually quite rare with a prevalence of less than 5% in mul-
tiple studies [68, 69].
A more appropriate and descriptive term for persistent
agonist-induced platelet activation despite aspirin therapy
is “high on-treatment platelet reactivity” (HTPR). Activated
platelets produce the eicosanoid thromboxane A2 (TXA2),
which creates a local positive-feedback loop that ampliﬁes
the activation response of the platelets to most agonists as
well as activating bystander quiescent platelets. Aspirin irre-
versibly inhibits COX-1, the key enzyme in the conversion
of arachidonic acid into TXA2 and thus interferes with the
thromboxane feedback loop (Figure 1). Aspirin, therefore,
limits the platelet response to weak agonists such as ADP and
collagen though potent platelet agonists, such as thrombin,
can still elicit strong platelet activation [70].
Due to the multiple pathophysiological mechanisms dis-
cussed above, patients with DM have hyperreactive platelets
that are more sensitive to activation even by relatively weak
agonists. As a result, even though aspirin may eﬀectively
block the TXA2 positive feedback loop, platelets of aﬀected
patients continue to manifest HTPR that places them at ele-
vated risk of future thrombotic events. The inability of as-
pirin monotherapy to suﬃciently blunt platelet reactivity
provides the rationale for dual antiplatelet therapy in certain
patients at high-risk of thrombotic events, such as patients
with acute coronary syndrome (ACS) or undergoing PCI
[71] and drives the search for more potent and speciﬁc anti-
platelet agents with a more consistent platelet suppressing
eﬀect.
5.1.Thienopyridines—Clopidogrel. SimilartoTXA2,ADPal-
so exerts a positive feedback on platelet reactivity. Platelet ac-
tivation leads to the release of adenosine diphosphate (ADP)
fromthedensegranulesthatbindstoplateletP2Y1 andP2Y12
receptors, potentiating platelet activation. The thienopy-
ridines were the ﬁrst class of alternative antiplatelet agents
that became available and irreversibly inhibit the P2Y12 (but
not the P2Y1) ADP platelet receptor, thus preventing the
positive feedback ampliﬁcation of agonist-induced platelet
activation. The ﬁrst thienopyridine compound, ticlopidine,
was associated with noninsigniﬁcant rates of hematologicInternational Journal of Endocrinology 5
side eﬀects, such as neutropenia and thrombotic thrombocy-
topenic purpura, and was superseded by the better tolerated
second-generation agent, clopidogrel.
Patients with a high-risk of thrombotic complications,
such as post-ACS or undergoing PCI, have been shown to
beneﬁt from aggressive dual antiplatelet therapy (DAT) con-
sisting of aspirin in conjunction with clopidogrel. In the
landmarkClopidogrelinUnstableAnginatoPreventRecurrent
Events (CURE) study of ACS patients, patients with DM
had a higher absolute risk reduction of primary outcome
(16.7% to 14.2%) than non-DM patients (9.9% to 7.9%),
albeit with a lower relative risk reduction from clopidogrel
therapy compared to the overall cohort (15% versus 20%,
resp.) [71, 72].
Clopidogrel does, however, have a number of drawbacks.
It has a relatively slow onset of antiplatelet action and large
inter-patient variability of platelet response due to variations
in drug metabolism. Both ticlopidine and clopidogrel are
prodrugs that require metabolic activation via a two-step
process involving cytochrome P450 (CYP) isoenzymes. Poly-
morphismsingenesencodingforseveraloftheCYPenzymes
cause ineﬀective or even absent metabolic activation of clo-
pidogrel in some patients resulting in HTPR. Patients with
HTPR, despite treatment with aspirin and clopidogrel are
known to be at increased risk of thromboembolic compli-
cations after drug eluting stent implantation [73–76]. Post-
treatment platelet reactivity assessment with the VerifyNow
P2Y12 system (Accumetrix, Inc., San Diego, Calif, USA) gives
particularly good predictability of such thrombotic events
[77].
DM has been found to be a predictor of HTPR despite
clopidogrel therapy in a number of studies and populations
[6,78,79].In the OptimizingAntiplateletTherapyinDiabetes
Mellitus (OPTIMUS) trial, two thirds of diabetic patients
were considered to have suboptimal response to aspirin
and clopidogrel DAT, deﬁned as a >50% residual platelet
aggregation following ADP agonist stimulation. These poor
responders had signiﬁcant platelet reactivity suppression
only with 150mg daily doses of clopidogrel but not the usual
75mg daily dose [80]. In a recent study, HTPR, despite clo-
pidogrel therapy in patients with DM, was associated with
a fourfold increase in periprocedural myocardial infarction
compared to DM patients with suppressed platelet reactivity
[81]. Interestingly, higher doses of clopidogrel (such as
600mg loading dose) may overcome HTPR in some patients
despite suboptimal glycemic control [82].
The HTPR problem may be further compounded by DM
therapy. A recent study found that DM patients on sulfon-
ylureas had a more than 2-fold higher rate of HTPR on clo-
pidogrel, possibly due to competition of the two drugs for
metabolism by the CYP2C9 cytochrome isoenzyme leading
toreducedbiotransformationofclopidogreltoitsactivemet-
abolite [83].
It is thought that the principal underlying pathophysi-
ological abnormality responsible for the increased rates of
clopidogrel HTPR in DM is that platelets from patients with
DM have lower levels of cAMP compared with nondiabetics.
Lower baseline cAMP leads to upregulated P2Y12 signaling
and, consequently, a lower degree of platelet inhibition by
P2Y12 antagonists. Increasing baseline platelet cAMP levels
would, therefore, seem a reasonable approach in reversing
this inherent resistance of DM platelets to P2Y12 inhibition.
5.2. Use of Cilostazol to Overcome Clopidogrel Platelet Re-
sistance in Diabetes. Cilostazol is a phosphodiesterase-3 in-
hibitor that increases intraplatelet cAMP levels and could
therefore be theorized to help overcome platelet resistance to
P2Y12 inhibition [84]. As expected, in the ACCEL-RESIST-
ANCE study, cilostazol reduced platelet activity more eﬀec-
tively than doubling the standard dose of clopidogrel to
150mg in patients with high platelet activity following clopi-
dogrel loading [85]. Increased inhibition of platelet P2Y12
signaling by the addition of 100mg cilostazol to DAT in type
2 DM patients following PCI was also demonstrated in the
randomized double-blind placebo controlled OPTIMUS-2
study [86]. This increased platelet inhibition translated into
a favorable clinical outcome in the DECREASE registry of
almost 3,100 patients treated with aspirin/clopidogrel DAT
or DAT plus cilostazol following PCI with a drug-eluting
stent [87]. Triple antiplatelet therapy (TAT) with cilostazol
signiﬁcantlyreduced12-monthrisksofstentthrombosisand
MI compared with DAT without increased risk of bleeding
complications.
Interestingly, the recent CILON-T trial recruited 960
patients with ACS receiving DES and randomized them in an
open-label fashion to DAT (aspirin and clopidogrel) or TAT
(aspirin, clopidogrel, and cilostazol) [88]. Approximately
one third of these patients had DM and half presented
with ACS. The addition of cilostazol enhanced DAT platelet
inhibition but there was no diﬀerence in composite adverse
events at 6 months in the entire cohort or in the subgroup
of DM patients. The authors hypothesized that the positive
chronotropic eﬀect of cilostazol may have had deleterious
eﬀects in the acute post-ACS setting that masked any favor-
able antiplatelet action. Interestingly, a genomics subgroup
analysis of CILON-T revealed that patients with speciﬁc
cytochrome P450 polymorphisms leading to impaired clopi-
dogrel activation had higher rates of HTPR if they were
randomized to DAT, but not if they received TAT [89]. This
important ﬁnding suggests that HTPR may arise from the
dysregulation of platelet activation mechanisms, as found in
patients with DM, independently of the patient’s ability to
activateclopidogrel.Itisalsonoteworthythatfemalepatients
(atlowerriskofevents),andelderlypatients(athigherriskof
bleeding complications) had more favorable outcomes with
DAT rather than with triple therapy including cilostazol.
Although cilostazol may have some beneﬁcial eﬀect in
DM patients by improving platelet response to DAT, there
are concerns regarding its use in ACS. It is, furthermore,
contraindicated in patients with congestive heart failure,
further limiting its utility in this acute setting.
5.3. Newer Antiplatelet Agents in DM Patients Undergoing
PCI. Diabetic patients with ACS have been shown to beneﬁt
from an early invasive strategy by PCI and derive a greater
beneﬁt from powerful platelet inhibition with glycoprotein
IIb/IIIa receptor antagonists (GPRAs) than patients without
DM [90]. In real-world clinical practice, however, patients6 International Journal of Endocrinology
with DM are oﬀered invasive therapy and GPRAs even less
frequently than nondiabetics [91]. The reason for this dis-
crepancyis unclear butmay be due to the higher incidence of
moderate-to-severe renal impairment in DM patients [92].
Furthermore, the role of GPRAs in the management of these
patients may need to be revised in view of the emergence of
newer, faster acting and potent antiplatelet agents.
Prasugrel. Prasugrel is a third-generation thienopyridine
antiplatelet agent that has received approval by the US
Food and Drug Administration (FDA) and the European
Medicines Agency (EMEA). Like clopidogrel and ticlopidine,
prasugrel is a pro-drug that requires metabolic activation.
Unlike these other agents, however, prasugrel is activated
by a one-step hepatic reaction that is unaﬀected by CYP
polymorphisms [93, 94]. This leads to more rapid and con-
sistent antiplatelet eﬀects compared to either ticlopidine or
clopidogrel. The Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition With Prasugrel-
ThrombolysisinMyocardialInfarction38(TRITON-TIMI38)
enrolled 13,608 patients with intermediate-to-high-risk ACS
or ST elevation MI undergoing PCI who were randomized
to clopidogrel versus prasugrel. A subgroup analysis of
patients with DM from this study showed that these patients
beneﬁted from a higher reduction in the primary end point
(a composite of cardiovascular death, myocardial infarction,
and stroke) than subjects without DM (hazard ratio—HR
0.72 versus 0.86, P<0.001), particularly if on insulin
therapy (HR 0.63, P = 0.009). The DM patients also had
no signiﬁcant increase in hemorrhagic complications unlike
the non-DM subjects [95]. Consequently, the net clinical
beneﬁt from prasugrel was greater for DM patients than for
those without DM. Based on these ﬁndings, prasugrel was
oﬃcially endorsed by the UK National Institute for Health
and Clinical Excellence (NICE) in October 2009 for limited
use in combination with aspirin in high-risk ACS patients
undergoing PCI (http://www.nice.org.uk/TA182). Along
with patients undergoing primary PCI for ST elevation MI
(STEMI) and patients with prior stent thrombosis whilst on
clopidogrel therapy, patients with DM were singled out as
a patient group most likely to beneﬁt from this enhanced
antiplatelet therapy. In the USA, the joint ACC/AHA/SCAI
guidelines endorse the use of prasugrel for patients with
STEMI undergoing PCI unless this is contraindicated due to
a prior history of stroke or transient ischemic attack [96].
Nonthienopyridine P2Y12 Receptor Antagonis. Nonthienopy-
ridine P2Y12 Receptor Antagonis including ticagrelor, can-
grelor and elinogrel, that do not require metabolic activation
are also being investigated. The phase 3 CHAMPION trials
of the short-acting intravenous reversible P2Y12 inhibitor
cangrelor were terminated due to poor interim results, while
a phase 3 trial of elinogrel, unique in having both an oral and
intravenous preparation, is in the planning stage [97, 98].
Ticagrelor, a member of a new cyclopentyl triazolo pyrim-
idine class of antiplatelet drugs has been more extensively
investigated. It is an orally active adenosine triphosphate
(ATP) derivative that reversibly inhibits the P2Y12 ADP
receptor. It provides more consistent platelet inhibition than
clopidogrel, as it does not require metabolic activation that
may be aﬀected by genetic polymorphisms, and its metab-
olite is also an active P2Y12 inhibitor [99]. It is also a more
potent agent, leading to 30% more platelet inhibition than
clopidogrel [100] and has a more rapid onset and oﬀset of
antiplatelet eﬀect [101]. The phase 3 PLATO (PLATelet inhi-
bition and patient Outcomes) trial randomized more than
18,500patientswithSTEMIorNSTEMIbetweenclopidogrel
and ticagrelor [102]. Overall, ticagrelor was associated with
a lower composite endpoint of cardiovascular death, MI, or
stroke with no increase in major bleeding. A subgroup anal-
ysis of PLATO data showed that DM patients with ACS,
representingapproximately25%ofthecohort,alsobeneﬁted
from a greater primary endpoint reduction with ticagrelor
than clopidogrel irrespective of glycemic control. Addition-
ally,thesepatients enjoyedareductionofcoronaryarteryby-
pass related bleeding, the latter being likely due to the revers-
ible nature of P2Y12 inhibition by ticagrelor [103]. Side
eﬀects of note were asymptomatic ventricular pauses and
dyspnea that proved clinically limiting and led to drug dis-
continuation in 1% of patients. Nonetheless, underweight
patients (below their respective gender median), patients not
on lipid-lowering drugs at randomization, and North Amer-
ican patients had notably lower or no beneﬁt from ticagrelor
treatment. The latter ﬁnding, postulated to be related to the
higher dose of aspirin used in North American patients, led
the US Food and Drug Administration (FDA) to decline
initial approval of the drug pending further review of the da-
ta, expected later this year.
Notably, in both the TRITON-TIMI 38 and the PLATO
trials, the newer agents were predominantly compared to
“standard” clopidogrel dosing consisting of a 300mg load
followed by 75mg daily maintenance. In the more recent
OASIS-7 (CURRENT) trial of ACS patients undergoing PCI,
a “high-dose” clopidogrel regimen (600mg loading and
150mg daily for the ﬁrst week after PCI) reduced throm-
boticendpointscomparedtothe“standard”dosingandmar-
ginally improved a composite primary outcome of cardio-
vascular death, myocardial infarction, or stroke at 30 days
post-PCI. Although this result is an analysis of the PCI
subgroup it is consistent with a meta-analysis of previous
studies [104]. None of the TRITON-TIMI 38 and fewer
than 20% of patients in the PLATO trial received 600mg
clopidogrel; consequently, the relative beneﬁt of prasugrel or
ticagrelorcomparedtohigh-doseclopidogrelremainsuncer-
tain. Nonetheless, in the GRAVITAS study 5,400 patients un-
dergoing, predominantly elective, PCI had platelet function
testing using the Verify Now assay (Accumetrics, Inc., San
Diego, Calif, USA). Those found to have HTPR despite
DAT, a ﬁnding signiﬁcantly more prominent in the DM sub-
group, were randomized to standard DAT or high-dose clo-
pidogrel loading and double-dose clopidogrel daily for 6
months. Although patients who were treated with higher
dosesofclopidogrel tendedtohavelowerP2Y12 plateletreac-
tivity there was no diﬀerence in the primary endpoint of car-
diovasculardeath,myocardialinfarction,andstentthrombo-
sis [105]. A proposed mechanism for this failure is that high-
dose clopidogrel is insuﬃcient to overcome platelet hyper-
reactivity in these patients who may fare better with moreInternational Journal of Endocrinology 7
Table 1: A summary of key antiplatelet drug clinical trials in patients with diabetes mellitus.
Study N (DM/total) Setting Groups Endpoint
Follow-up period Pertinent ﬁndings
Clopidogrel
CURE
Clopidogrel in
unstable Angina to
prevent recurrent
events
2,838/12,562 UA, NSTEMI
Clopidogrel (300mg LD,
75mg MD) versus
placebo in addition to
standard aspirin therapy.
RCT
Composite
cardiovascular death,
MI, or stroke.
Mean followup 9
months
Higher absolute risk reduction of
primary outcome (16.7% to
14.2%) in DM than non-DM
patients (9.9% to 7.9%), but a
clopidogrel beneﬁt of borderline
statistical signiﬁcance with lower
relative risk reduction compared
to the overall cohort (15% versus
20% resp.)
OPTIMUS
Optimizing
antiplatelet therapy
in Diabetes Mellitus
40/40
DM patients
on DAT with
HTPR
Clopidogrel 75mg MD
versus Clopidogrel
150mg MD. RCT
Platelet function testing
at 60 days
Two thirds (40/64) of screened
DM patients had “suboptimal
response to clopidogrel” 75mg
(HTPR).
Platelet aggregation in response
to ADP was signiﬁcantly reduced
in DM patients receiving
clopidogrel 150mg compared
with the 75mg group
(P = 0.002)
OASIS-7 (CURRENT)
Clopidogrel and
Aspirin optimal dose
usage to reduce
recurrent
events—seventh
organization to assess
strategies in ischemic
syndromes
5,880/25,087
ACS patients
planned for
invasive
strategy
Clopidogrel (600mg LD,
150mg MD for 6 days,
then 75mg MD) versus
Clopidogrel (300mg LD,
75mg MD).
Aspirin (300–325mg
MD) versus aspirin
(75–100mg MD).
2 × 2f a c t o r i a ld e s i g n
Composite
cardiovascular death,
MI, or stroke.
30 days
No overall statistical signiﬁcance
between the two clopidogrel
regimes on primary endpoint.
No signiﬁcant diﬀerence between
higher-dose and lower-dose
aspirin with respect to the
primary outcome.
Reduced secondary outcome of
stent thrombosis with high-dose
Clopidogrel in subset of patients
undergoing PCI
GRAVITAS
Gauging
responsiveness with a
verifynow
assay—impact on
Thrombosis and
safety
1,004/2,214
Patients post
PCI with
HTPR on
DAT by
verifynow
assay
Clopidogrel (75mg MD)
versus Clopidogrel
(repeat 600mg LD,
150mg MD)
Composite
cardiovascular death,
MI, stent thrombosis.
Bleeding safety
endpoint.
6m o n t h s
41% of screened patients (2214
of 5429) had HTPR on
Clopidogrel 75mg.
Lower P2Y12 platelet reactivity
with higher-dose Clopidogrel but
no diﬀerence in the primary
composite endpoint at 6 months
CHARISMA
Clopidogrel for High
Atherothrombotic
risk and ischemic
stabilization,
management, and
avoidance
6,556/15,603
Patients with
stable cardio-
vascular
disease or
multiple risk
factors
Clopidogrel 75mg
versus placebo in
addition to aspirin
75–162mg daily
Composite
cardiovascular death,
MI, stroke.
Median 28 months
follow-up
No diﬀerence in primary
endpoint between aspirin and
DAT.
Increased hemorrhagic events
with DAT.
Increased mortality in patients
with DM nephropathy treated
with DAT
Cilostazol
ACCEL/RESISTANCE
Adjunctive Cilostazol
versus high
maintenance dose
Clopidogrel in
patients with
Clopidogrel resistance
14/60
Patients with
HTPR after
clopidogrel
300mg
loading
Clopidogrel 75mg +
cilostazol 100mg bd
versus Clopidogrel
150mg. All patients on
aspirin 200mg/day. RCT
Platelet function testing
at 30 days
Adjunctive cilostazol reduced the
rate of HTPR and intensiﬁed
platelet inhibition as compared
with high-maintenance dose
clopidogrel 150mg/day8 International Journal of Endocrinology
Table 1: Continued.
Study N (DM/total) Setting Groups Endpoint.
Follow-up period Pertinent ﬁndings
OPTIMUS-2
Optimizing
antiplatelet therapy
in diabetes mellitus 2
20/20
DM patients
on DAT
(aspirin
81mg,
clopidogrel
75mg daily)
Adjunctive Cilostazol
100mg bd versus
placebo.
2-week cross-over
double-blind RCT
design
Platelet function
Enhanced P2Y12 platelet receptor
signaling inhibition with
cilostazol in adjunct to standard
DAT.
Signiﬁcant side eﬀects with
cilostazol with high rate of drug
withdrawal
DECREASE Registry
drug-eluting stenting
followed by
Cilostazol treatment
reduces adverse
serious cardiac events
867/3,099
Patients after
DES
implantation
DAT (aspirin,and
clopidogrel) versus TAT
(aspirin, clopidogrel and
cilostazol).
Registry
Death, MI and stent
thrombosis.
12 months
Cilostazol signiﬁcantly reduced
the 12-month risk of stent
thrombosis and MI after DES
implantation when added to
DAT.
No increase in major or minor
bleeding complications
CILON-T
Inﬂuence of
CILostazol-based
triple antiplatelet
therapy ON ischemic
complication after
drug-eluting stent
implantation
307/960
Patients after
DES
implantation
DAT (aspirin and
clopidogrel) versus TAT
(aspirin, clopidogrel and
cilostazol).
Open-label, blind
evaluation
Cardiac death, MI,
ischemic stroke, and
TLR at 6 months
Enhanced platelet inhibition
with TAT but no diﬀerence in
composite adverse events at 6
months (entire cohort or DM
patients).
Higher adverse events with TAT
versus DAT in females and
elderly patients
Prasugrel
TRITON-TIMI 38
Trial to assess
improvement in
therapeutic outcomes
by optimizing platelet
inhibition With
Prasugrel-
Thrombolysis in
Myocardial infarction
38
3,146/3,608
Patients with
moderate-to-
high-risk
UA/NSTEMI,
STEMI for
PCI
Clopidogrel (300mg LD
and 75mg MD) versus
Prasugrel (60mg LD and
10mg MD)
CV death, MI and
stroke.
Bleeding safety endpoint
DM patients on prasugrel had
higher reduction in endpoint
compared to clopidogrel than
non-DM patients (HR 0.72
versus 0.86, P<0.001).
Beneﬁt of prasugrel was greater
amongst DM patients on insulin
(HR, 0.63; P = 0.009).
Patients without DM had
signiﬁcantly increased risk of
TIMI major hemorrhage on
prasugrel versus clopidogrel
(1.6% versus 2.4%; P = 0.02) but
DM patients had similar
bleeding rates on the two drugs
(P = 0.81).
Greater net treatment beneﬁt
with prasugrel versus clopidogrel
in DM patients
Ticagrelor
PLATO
platelet inhibition
and patient outcomes
4,662/18,624
Patients with
moderate-to-
high-risk
UA/NSTEMI,
STEMI for
PCI
Clopidogrel (300mg LD
and 75mg MD) versus
Ticagrelor (180mg LD
a n d9 0m gb dM D )
CV death, MI and
stroke.
Bleeding safety
endpoint.
6–12months
Ticagrelor was associated with a
lower composite endpoint with
no increase in bleeding in the
entire cohort as well as DM
patients.
Eﬀects were irrespective of DM
status, insulin treatment, and
glycemic control
ACS: acute coronary syndrome, ADP: adenosine diphosphate, bd: twice daily, DAT: dual antiplatelet therapy, DES: drug-eluting stent, DM: diabetes mellitus,
HR: hazard ratio, HTPR: high on-treatment platelet reactivity, LD: loading dose, MD: maintenance dose, MI: myocardial infarction, NSTEMI: non-ST
elevation MI, RCT: randomized control trial, STEMI: ST-elevation MI, TAT: triple antiplatelet therapy, UA: unstable angina.International Journal of Endocrinology 9
potent therapy such as with prasugrel, ticagrelor, or other
novel agents.
As many of the deranged intracellular pathways in DM
contribute to P2Y12 inhibition, it is hoped that agents that
can inhibit alternative activation pathways may be helpful in
DM patients. One such potential novel target is the protease-
activated receptor 1 that mediates the eﬀect of thrombin,
the most potent physiologic platelet activator. Thrombin
receptor antagonism has the additional theoretical beneﬁt of
blocking the cellular eﬀects of thrombin without inhibiting
the thrombin-mediated cleavage of ﬁbrinogen (that is the
ﬁnal stent of the coagulation cascade) and may, therefore,
cause less bleeding than other antithrombotic agents [106–
109]. At least one such agent is currently being trialed in DM
patients (clinicaltrials.gov: NCT00855374). Similarly, the
thromboxane receptor provides a possible therapeutic tar-
getinblockingtheTXA2feedbackloop.ATPselectiveantag-
onist is currently in phase III clinical trial for prevention
of recurrent ischemic complications in patients with prior
transient ischemic cerebral events [110].
5.4. Antiplatelet Therapy in DM Patients with Stable Vascu-
lopathy. It must, ﬁnally, be noted that although DM pa-
tients have higher baseline platelet reactivity, this does not
appear suﬃcient to warrant aggressive antiplatelet therapy
in the chronically stable DM patient. DM patients with
asymptomatic, stable coronary, cerebrovascular, or periph-
eral vascular disease did not have a reduction of MI, stroke
or cardiovascular death with dual antiplatelet therapy (DAT)
of aspirin and clopidogrel compared to aspirin alone in
the CHARISMA trial [72]. DAT was, however, associated
with increased hemorrhagic events. Interestingly, a posthoc
analysis of this large trial suggested that, in the presence
of diabetic nephropathy, the addition of clopidogrel to the
antiplatelet regime of such patients was, in fact, associated
with an increase in overall cardiovascular mortality, though
the pathophysiological mechanism of this ﬁnding is unclear
[111, 112]. Similarly, meta-analyses of the use of aspirin for
the primary prevention of cardiovascular events suggest a
modest reduction in cardiovascular events (MI and stroke)
[113]. The data remain inconclusive to recommend aspirin
use for primary prevention in all DM patients, though
it should be prescribed to DM patients at >10% 10-year
risk of cardiovascular disease and considered in patients
at intermediate (5%–10%) risk according to the recent
position statement of the American Diabetes Association
[114]( Table 1).
6. Conclusion
Patients with DM have evidence of platelet hyperreactivity
and increased baseline platelet activation. This results from a
combinationoffactorsincludingtheeﬀectsofinsulin,hyper-
glycemia, hyperlipidemia, endothelial dysfunction, oxidative
stress, and inﬂammatory state. As our understanding of the
molecular and genetic bases underpinning pathophysiologi-
cal and therapeutic interactions expands, we can move closer
towards individualized patient treatment.
Antiplatelet drugs interfere with platelet activation in the
setting of pathologic atherothrombosis, but potentially also
during physiologic hemostasis. There is currently no “mag-
ic bullet” antiplatelet agent that can eﬀectively abolish athe-
rothrombosis with no hemorrhagic penalty. The group of
thrombin receptor antagonists is promising in this respect
as this pathway may be of most signiﬁcance in pathologic
atherothrombosis rather than physiologic hemostasis. Cur-
rently bleeding is, therefore, a major factor to determine the
risk-to-beneﬁt utility of present and upcoming antiplatelet
drugs. In view of the enhanced platelet functionality in DM
patients, this ratio and, consequently, the choice of anti-
platelet agents may diﬀer from the general population.
Patients with DM represent an important subgroup who
may enjoy a greater net clinical beneﬁt from a more po-
tent antiplatelet regimen. The beneﬁt DM patients derive
from early invasive therapy and use of GPIIb/IIIa receptor
antagonists is well established, but these agents are under-
utilized in clinical practice. The addition of cilostazol to
aspirin/clopidogrel dual antiplatelet therapy in patients with
DM merits consideration though there remain concerns for
its use in the ACS DM population. The results from the
large clinical studies of prasugrel (TRITON-TIMI 38)a n d
ticagrelor (PLATO) appear favorable for the use of these
agents in conjunction with aspirin following PCI in DM
patients. Although analysis of the diabetic patient subgroup
in these landmark studies was prespeciﬁed, randomization
was not performed. Consequently, outcome data from trials
of these novel antiplatelet therapies, speciﬁcally recruiting
high-risk DM patients, are eagerly awaited.
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